BC Extra | Jan 7, 2020
Financial News

Jan. 7 Financial Quick Takes: Deep Genomics raises $40M; plus Arcutis, Kintor file for IPOs, TwinStrand and RootPath

Future Ventures leads Deep Genomics’ $40M series B   Looking to submit INDs for two programs this year, Deep Genomics Inc. raised $40 million in a series B round led by Future Ventures, with participation...
BC Extra | Oct 22, 2019
Financial News

Crossover investors help Arcutis raise $95M to advance PDE-4 inhibitor for psoriasis

Arcutis raised $94.5 million in a series C financing to advance lead product ARQ-151, a topical formulation of the PDE-4 inhibitor roflumilast, through Phase III trials for mild-to-moderate psoriasis. Arcutis Biotherapeutics Inc. co-founder Chairman Bhaskar...
BC Extra | Jul 22, 2019
Clinical News

July 22 Clinical Quick Takes: Positive psoriasis data for Arcutis; plus Intec and Renovo

ARQ-151 meets Phase IIb endpoint  Arcutis Inc. (Westlake Village, Calif.) said high and low daily doses of ARQ-151 for six weeks met the primary endpoint in a Phase IIb trial of reducing signs of plaque...
BioCentury | Jun 21, 2019
Emerging Company Profile

Arcutis: Reformulating dermatology

Arcutis Inc. is using its founders’ topical reformulation expertise to develop safer and less expensive therapeutics against known targets to treat dermatology patients who aren’t eligible for biologics. Frazier Healthcare launched the company in 2016...
BC Innovations | Jan 8, 2019
Distillery Therapeutics

Transplant

INDICATION: Heart transplant rejection; graft rejection Mouse studies suggest inhibiting CORO1A or its downstream mediator PDE-4 could help treat heart transplant and skin graft rejection. In a mouse model of heart transplantation, systemic CORO1A knockout...
BC Innovations | Mar 21, 2017
Distillery Therapeutics

Pulmonary

INDICATION: Chronic obstructive pulmonary disease (COPD) In vitro and cell culture studies identified a dual-acting PDE-4 inhibitor/ ADRB2 agonist that could help treat COPD. In in vitro activity assays, a quinolone analog conjugated to a...
BioCentury | May 30, 2016
Strategy

Taking Takeda global

Two years after joining Takeda Pharmaceutical Co. Ltd. , Christophe Weber has narrowed the company's therapeutic focus, expanded the executive team and reorganized its approach to market with the aim of transforming the company into a...
BC Week In Review | Dec 21, 2015
Company News

Takeda, AstraZeneca deal

AstraZeneca will acquire Takeda’s core respiratory business, including Daliresp roflumilast, Alvesco ciclesonide, Omnaris ciclesonide nasal spray and seven undisclosed early pipeline products. Takeda will receive a $575 million upfront payment and will transfer about 200...
BC Extra | Dec 17, 2015
Top Story

AZ bulks up China operations, respiratory portfolio

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Wednesday it would build up its presence in China and acquire a global respiratory portfolio from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for $575 million in cash. AZ's growth in China...
BC Week In Review | Feb 23, 2015
Clinical News

Daliresp roflumilast: Phase III/IV data

The 1-year, double-blind, international Phase III/IV REACT trial in 1,945 patients showed that 500 µg daily oral Daxas plus a long-acting beta 2 agonist (LABA) and an inhaled corticosteroid (ICS) with or without a long-acting...
Items per page:
1 - 10 of 125